The Motley Fool

Why Goldman Sachs just put a sell rating on Fisher & Paykel shares

The healthcare sector has been one of the best-performing sectors for ASX share market investors over the past decade and given the tailwinds of ever greater public and private spending on healthcare it’s not hard to see why. Companies like Cochlear Ltd (ASX: COH), CSL Limited (ASX: CSL) and ResMed Inc. (ASX: RMD) have all thumped the market over that period. 

The Fisher & Paykel Healthcare Ltd (ASX: FPH) share price has also more than tripled over the past 5 years as the sleep treatment specialist grows sales, profits and dividends.

Today the ASX-listed shares change hands for $14.63, but could have some down days ahead if the analysts at Goldman Sachs are on the money with their $13.90 12-month share price target on the business. 

The price differential means Goldman’s has a sell rating on shares partly because it feels Fisher & Paykel could continue losing market share in the key space of treating sleep apnea via the sale of masks. It is also paring back its expectations for gross margin growth with margins being key drivers of analyst ratings for medical device businesses. 

However, on the plus side the analysts acknowledge they may be too bearish if Fisher & Paykel’s new face mask gains FDA approval sooner than expected and sales take off. 

These ASX shares have shot up 204% and even 954%, but we think they’re just getting started

The $700 billion “war on cash” is on… and even The New York Times is calling it “a goldmine of staggering proportions”…

That’s why The Motley Fool has just released a brand-new research report: “Leave Your Wallet at Home: 2 Stocks for the Digital Payments Revolution.” Inside, you’ll find 2 expert-picked ASX shares poised to profit from this sweeping tech revolution.

Heck, stock #1 is already up 204% in just the last two years. While Stock #2 has climbed an eye-watering 954% since 2015 alone…

Yet we’re convinced the sheer biggest returns could be still ahead, with 10X or more potential profits still on the table. Simply click the link below now and we’ll show you how to snap up this timely (and potentially highly profitable) new research for FREE.

Click here to snap up your copy of “Leave Your Wallet at Home: 2 Stocks for the Digital Payments Revolution.”

Tom Richardson owns shares of Cochlear Ltd., CSL Ltd., and ResMed Inc.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.